Telehealth ADHD Prescribing: What Psychiatric NPs Can Do in New York

If you’re a psychiatrist or PMHNP wondering whether you can legally prescribe Adderall, Vyvanse, or other ADHD medications through telehealth — or if you’re trying to figure out where you stand compared to other providers — you’re not alone. The regulatory landscape for ADHD prescribing has been in flux since the pandemic, and 2026 brings both opportunity and uncertainty.

The short answer: Yes, psychiatrists can prescribe ADHD medications via telehealth right now — but the rules depend on federal waivers that are currently extended through the end of 2025, and what happens in 2026 is still being decided. For PMHNPs, it depends heavily on which state you’re licensed in.

Let’s break down what’s actually happening with telehealth ADHD prescribing, where the regulations stand, and what it means for your practice.

The Federal Telehealth Landscape: Why ADHD Prescribing Is Different

ADHD medications like Adderall (amphetamine) and Ritalin (methylphenidate) are Schedule II controlled substances — the most tightly regulated prescription drugs outside of Schedule I. Under the Ryan Haight Act (2008), prescribing Schedule II drugs via telemedicine normally requires at least one in-person exam.

During COVID, that requirement was waived. The DEA allowed psychiatrists and other providers to prescribe stimulants entirely through telehealth, no in-person visit needed. That waiver has been extended multiple times — most recently through December 31, 2025 (www.axios.com).

What happens in 2026? Unless Congress passes permanent legislation or the DEA implements new rules (like a special telehealth registration system), we could revert to requiring in-person exams for new controlled substance patients. Right now, that’s the biggest question mark hanging over tele-ADHD practices.

For psychiatrists, this uncertainty is manageable — you can continue business as usual through 2025 and prepare contingencies (partnering with local clinics for in-person visits if needed). The demand for ADHD care isn’t going away, and telehealth has proven it works.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What Psychiatrists Can Do: Full Authority, Minimal Restrictions

As a psychiatrist (MD or DO), you have unrestricted prescriptive authority in every state. You don’t need supervision, collaborative agreements, or special permissions to prescribe Schedule II stimulants. Your scope is defined only by:

• Your DEA registration
• Your state medical license
• State-specific controlled substance permits (where required)
• Federal telehealth rules (currently flexible through 2025)

Clinically, you can manage ADHD entirely via telehealth:

• Conduct comprehensive diagnostic evaluations through video (using DSM-5 criteria, rating scales like ASRS or ADHD-RS)
• E-prescribe stimulants through EPCS-compliant platforms
• Monitor treatment with monthly follow-ups (standard for Schedule II refills)
• Check state Prescription Drug Monitoring Programs before prescribing
• Coordinate care (request vitals from PCPs, order labs if needed)

The telehealth exam itself is legitimate — a thorough video assessment, patient interview, collateral information (especially for pediatric cases), and standardized questionnaires satisfy the standard of care. You’re not cutting corners; you’re delivering the same quality evaluation remotely.

State-Specific Considerations for Psychiatrists

While your prescriptive authority is universal, state telehealth laws add nuances:

Florida explicitly allows telehealth prescribing of Schedule II drugs for psychiatric disorders — ADHD qualifies (www.flsenate.gov). This makes Florida one of the clearer states for tele-ADHD care.

Texas permits telehealth controlled substance prescribing for mental health conditions (not chronic pain), but requires live video — no audio-only calls for stimulants (www.cchpca.org). Texas also has some of the worst psychiatrist shortages in the country (1 psychiatrist per ~9,000 residents), so demand is massive (www.healingpsychiatryflorida.com).

New York has no additional telehealth restrictions beyond federal law, but mandates PDMP checks before every controlled prescription and requires e-prescribing for all meds. NY also has strong telehealth parity laws — you’ll get paid the same for virtual visits as in-person.

California follows federal guidelines and has mandated e-prescribing for controlled substances since 2022. CA is phasing in nurse practitioner independence, which may shift competitive dynamics, but psychiatrists remain essential for complex cases and independent prescribing.

Pennsylvania and Illinois also default to federal telehealth rules, with solid insurance coverage and parity. Both states have moderate psychiatrist supply in cities but significant rural gaps — telehealth is filling those gaps.

Bottom line: You need a state license where your patient is located (the patient’s physical location during the visit determines jurisdiction), and you must follow that state’s PDMP and e-prescribing rules. But no state outright bans psychiatrists from prescribing ADHD meds via telehealth when federal allowances are in place.

PMHNP vs Psychiatrist: Where Authority Diverges

This is where things get complicated. Nurse practitioners’ ability to prescribe ADHD medications varies dramatically by state, and these differences directly impact who can serve patients and how practices scale.

States Where PMHNPs Have Full or Near-Full Authority

New York: After 3,600 hours of supervised practice (~2 years), PMHNPs can practice and prescribe independently — including Schedule II stimulants. No collaborative agreement needed after that threshold. They check the same PDMPs, use the same e-prescribing systems, and manage ADHD just like a psychiatrist (rxagent.co).

Illinois: NPs can obtain Full Practice Authority after 4,000 hours of experience and additional training. Once granted, they prescribe Schedule II-V drugs independently. Illinois carved out a physician consultation requirement for Schedule II narcotics (opioids), but stimulants for ADHD aren’t explicitly covered by that — meaning experienced PMHNPs can manage ADHD meds solo (rxagent.co).

California: Transitioning to independence. Experienced NPs (≥3 years, 4,600 hours) can apply for independent ‘104 NP’ status starting in 2023. They still need to complete a pharmacology course for Schedule II authority, but once independent, they can prescribe stimulants without physician oversight (rxagent.co).

States Where PMHNPs Face Restrictions

Texas: This is the most restrictive. Texas law prohibits NPs from prescribing Schedule II controlled substances in outpatient settings — period. The only exceptions are hospitalized patients, emergency rooms, or hospice (rxagent.co).

That means a PMHNP in Texas cannot write an Adderall prescription for a routine ADHD patient, even with a collaborative agreement. Only physicians can. NPs can manage therapy, coordinate care, or prescribe non-stimulant ADHD meds (like atomoxetine or bupropion), but the core stimulant prescribing must come from an MD.

Florida: NPs require a collaborative protocol with a physician (for psychiatric NPs, that must be a psychiatrist). Florida limits NPs to a 7-day supply of Schedule II drugs — except when a ‘psychiatric nurse’ prescribes psychotropic controlled substances under a psychiatrist’s protocol, in which case the 7-day limit doesn’t apply (www.leg.state.fl.us).

Translation: A Florida PMHNP working with a psychiatrist can prescribe 30-day supplies of Adderall for ADHD patients. But they cannot practice independently, and the psychiatrist collaboration is legally required.

Pennsylvania: NPs need collaborative agreements with physicians. For Schedule II prescriptions, they can only write a 72-hour initial supply and must notify the collaborating physician; ongoing refills are limited to 30-day supplies, with physician re-evaluation required for continuation (rxagent.co).

This creates workflow friction — many PA practices have the psychiatrist handle the initial stimulant prescription, then the NP manages follow-ups. It’s workable, but it requires tight coordination.

Why This Matters for Your Practice

If you’re a psychiatrist, you’re in high demand everywhere — but especially in states like Texas and Florida where NPs can’t independently prescribe stimulants. You become the bottleneck and the solution. Telehealth platforms need psychiatrists to serve those states, and you can command higher compensation or more flexibility because your scope isn’t restricted.

If you’re a PMHNP, your opportunities depend on geography. In New York or Illinois, you can build an independent ADHD practice after gaining experience. In Texas, you’ll need to partner with a psychiatrist or focus on non-stimulant treatment and therapy. In Florida or Pennsylvania, you can prescribe ADHD meds but only under physician oversight — which might limit your autonomy but also provides collaborative support.

For platforms like Klarity, understanding these state differences is critical. Some states require recruiting psychiatrists to legally serve the market; others can leverage experienced NPs. Both provider types bring value, but the regulatory constraints shape the care model.

The Economics of ADHD Telehealth: What Reimbursement Looks Like

One of the best developments in telehealth over the past few years: insurance reimbursement parity is now nearly universal (behavehealth.com).

Medicare, Medicaid, and most commercial insurers pay the same rate for telehealth psychiatric visits as in-person visits. This wasn’t true pre-2020, but pandemic-era changes stuck.

What You’ll Actually Get Paid

For medication management visits (the bread and butter of ADHD care), psychiatrists typically bill:

• 99213 (15-minute established patient visit): ~$89-95 from Medicare, often $100-130 from commercial payers (therathink.com)
• 99214 (25-minute moderate complexity visit): ~$125-136 from Medicare, $140-180+ from commercial plans
• 90792 (Initial psychiatric evaluation with meds): ~$188-202 from Medicare (therathink.com)

Medicaid pays less — often $40-65 for a med check depending on the state (therathink.com) — but volume and telehealth efficiency can offset lower rates.

Psychiatrists are reimbursed at higher levels than other provider types for the same services (therathink.com). NPs under Medicare get 85% of the physician rate if billing independently (though many collaborative models bill under the MD to capture full rates).

Why This Beats DIY Marketing

Here’s the part most providers get wrong when evaluating telehealth platforms: patient acquisition cost.

If you try to build your own ADHD practice through SEO, Google Ads, or directory listings, you’re looking at:

• SEO: 6-12 months before you see meaningful patient flow, plus ongoing investment in content, technical optimization, and often consultant fees ($1,500-3,000/month for quality work)
• Google Ads: Mental health keywords cost $15-40+ per click. Most clicks don’t convert. Realistic cost per booked patient: $200-400+ once you factor in ad spend, wasted clicks, and no-shows from cold leads
• Directories (Psychology Today, Zocdoc): Monthly subscription fees ($30-100/month) plus listing fees or per-booking charges ($35-100 per patient for Zocdoc). You’re also competing with hundreds of other providers on the same page

Add it all up — consultant fees, ad spend testing and optimization, staff time qualifying leads, months of zero results while SEO ramps up — and most solo providers spend $3,000-5,000/month on marketing with uncertain ROI.

Platforms like Klarity use a pay-per-appointment model: you pay a standard fee only when a qualified patient actually books with you. No upfront marketing spend. No monthly subscriptions. No gambling on whether your SEO will work or your Google Ads will convert.

The patients are pre-qualified — matched to your specialty, availability, and the insurance they’re trying to use. The platform handles the acquisition cost through scale (they can afford to spend on marketing across thousands of providers) and passes along only the patients that fit.

You’re paying for guaranteed results — a booked appointment — instead of paying to try to get results. That’s a fundamentally different risk profile, especially if you’re starting out or scaling a practice.

The Practical Workflow: How ADHD Telehealth Actually Works

Let’s walk through what managing ADHD via telehealth looks like day-to-day, because the regulatory complexity makes some providers worry it’s not feasible. It absolutely is.

Initial Evaluation

You conduct a comprehensive video assessment (typically 45-60 minutes):

• Clinical interview covering symptom history (childhood onset, current impairment across settings)
• Standardized rating scales (ASRS for adults, Vanderbilt or Conners for kids — these can be sent electronically pre-visit)
• Review of collateral information (school records, prior evaluations, family input for pediatric cases)
• Mental status exam (attention, impulsivity observable on video)
• Screening for comorbidities (anxiety, depression, substance use)
• Check PDMP for any prior controlled substance history

You document the evaluation thoroughly (required for Schedule II justification) and obtain informed consent covering stimulant risks (cardiovascular, abuse potential, side effects).

If the patient meets DSM-5 criteria for ADHD and there are no contraindications, you can prescribe.

E-Prescribing

You write the prescription through an EPCS-compliant platform (two-factor authentication required for controlled substances). Most telehealth EMRs handle this seamlessly — you’re not printing paper scripts or faxing.

The prescription goes directly to the patient’s pharmacy. Schedule II drugs can’t have refills, so you write for a 30-day supply (or up to 90 days using separate prescriptions with future fill dates if appropriate).

Ongoing Management

ADHD medication management typically involves monthly follow-ups (15-20 minute video visits):

• Symptom monitoring (rating scales again)
• Side effect checks (appetite, sleep, mood, blood pressure/heart rate — you ask the patient to self-monitor or get checked at a pharmacy/PCP)
• Dose adjustments as needed
• PDMP check (at least quarterly, or before each prescription depending on state law)
• Renewal of the 30-day prescription

Most patients stabilize on a dose within a few months, at which point visits might extend to every 2-3 months (though prescriptions still need to be written monthly due to Schedule II restrictions).

What About In-Person Requirements?

Right now, under the federal extension through 2025, you don’t need an in-person visit at all for new ADHD patients via telehealth.

If that changes in 2026 (Ryan Haight Act reinstated), you’d need to:

• Establish a relationship with local clinics or physicians who can do a one-time in-person exam for your telehealth patients, OR
• Use the DEA’s proposed ‘special registration’ pathway if/when it’s finalized (allowing you to skip in-person exams if you meet certain criteria)

Most telehealth platforms are preparing for both scenarios. It’s a solvable problem — not ideal, but not practice-ending.

Safeguarding Against Abuse

Given increased scrutiny on telehealth ADHD prescribing (some online companies got in trouble for overprescribing with minimal oversight), best practices include:

• Thorough evaluations — not 10-minute questionnaires
• Verification — confirm patient identity and location each visit
• PDMP checks — every prescription or at minimum quarterly
• Urine drug screens if there’s any concern about diversion or substance misuse
• Patient agreements outlining expectations and policies (some providers use controlled substance agreements)
• Coordination with primary care providers when possible

These aren’t just compliance checkboxes — they’re good medicine and they protect your license.

Market Realities: Demand, Shortages, and Where the Opportunity Is

ADHD diagnosis and treatment surged during the pandemic. Adult ADHD prescriptions jumped significantly in 2020-2022 as telehealth made it easier for people to seek help (apnews.com). That surge created two things:

1. Massive unmet demand — waitlists for psychiatrists and PMHNPs stretched for months
2. Medication shortages — Adderall and other stimulants have been intermittently backordered since late 2022 (www.axios.com)

For providers, this means:

• Patient volume is not a problem. If you’re licensed and taking new patients, you can fill your schedule quickly.
• Medication management is the bottleneck. Patients often can’t find providers who prescribe stimulants or who take their insurance. You’re solving a real access problem.
• Supply chain headaches. You’ll occasionally need to switch patients to alternative stimulants or coordinate with multiple pharmacies — frustrating, but manageable.

State-Specific Opportunities

Texas and Florida have the worst psychiatrist shortages — roughly 1 psychiatrist per 8,500-9,000 residents (www.healingpsychiatryflorida.com) (www.healingpsychiatryflorida.com). Both states also restrict NP prescribing, so psychiatrists are essential to serve those markets. If you’re licensed in TX or FL, you’re in a seller’s market.

New York has the best psychiatrist-to-population ratio (~1:2,900), but demand is still high and upstate/rural areas are underserved (www.healingpsychiatryflorida.com). NYC has competition, but also a massive patient base willing to pay for convenience.

Pennsylvania and Illinois have moderate supply in cities but rural gaps. Both states have solid telehealth infrastructure and insurance coverage, making them good markets for remote providers.

California is the largest state by population, with strong demand in urban areas and severe shortages in rural/inland regions. CA’s regulatory environment is evolving (NP independence increasing), but psychiatrists remain highly valued.

What This Means If You’re Joining a Telehealth Platform

When you evaluate a platform like Klarity for ADHD prescribing, here’s what matters:

1. Licensing support: Do they help you get licensed in multiple states (or do they operate only in states where you’re already licensed)? Multi-state licensure through compacts (Interstate Medical Licensure Compact for MDs, or state-by-state for NPs) expands your patient pool.

2. Compliance infrastructure: Does the platform handle PDMP checks, EPCS integration, informed consent workflows, and documentation templates? You shouldn’t be building your own compliance systems.

3. Patient quality: Are patients pre-screened and matched to your availability? Or are you fielding random inquiries and no-shows? The economics only work if the patients are qualified and serious.

4. Reimbursement model: Insurance-based (platform credentials you with payers) or cash-pay (platform charges patients directly)? Both can work, but insurance models provide volume and sustainability.

5. Schedule control: Can you set your own hours and patient load? Or are you locked into rigid scheduling? Flexibility is one of telehealth’s biggest draws — make sure it’s real.

6. Support for state-specific rules: If you’re a PMHNP in a state requiring physician collaboration, does the platform provide that? If you’re a psychiatrist in a state with strict PDMP requirements, does the platform integrate those checks into the workflow?

The platform should remove friction, not add it. Your job is to be a great clinician. The platform’s job is to handle patient acquisition, admin, compliance infrastructure, and billing — the stuff that bogs down solo practices.

The Bottom Line: Yes, You Can Prescribe ADHD Meds via Telehealth — And You Should

Here’s what you need to remember:

• Psychiatrists can prescribe ADHD medications via telehealth in every state, subject only to federal rules (currently flexible through 2025) and state licensing/PDMP requirements. Your authority is unrestricted.

• PMHNPs can prescribe ADHD meds in many states, but your scope depends entirely on state law. In New York, Illinois, and California (for experienced NPs), you’re nearly equal to a psychiatrist. In Texas, you can’t prescribe Schedule II stimulants at all. In Florida and Pennsylvania, you need physician collaboration.

• Reimbursement is solid. Telehealth parity is now standard, so you’ll get paid fairly for virtual visits. The economics are as good as or better than in-person practice (lower overhead, higher efficiency, no commute).

• Patient demand is massive. ADHD is underserved everywhere. Telehealth lets you reach patients who’ve been waiting months for care.

• The regulatory uncertainty for 2026 is real but manageable. The federal telehealth extension runs through end of 2025. After that, we may need in-person exams for new patients — or Congress may pass permanent rules. Either way, the core service (managing existing ADHD patients, prescribing refills, doing follow-ups) will remain viable via telehealth.

• Platforms beat DIY. Building your own patient pipeline costs $3,000-5,000/month in marketing with no guarantees. Paying per booked appointment is guaranteed ROI with zero upfront risk.

If you’re a psychiatrist or PMHNP wondering whether telehealth ADHD care is worth it: yes. The demand exists, the reimbursement is there, and the legal framework (while imperfect) supports it.

The question isn’t whether you can do this. It’s whether you’re going to sit on the sidelines while patients wait months for care — or step in and fill the gap.

Frequently Asked Questions

Can psychiatrists prescribe Adderall through telehealth in 2026?

Yes. As of early 2026, psychiatrists can prescribe Adderall and other Schedule II ADHD medications via telehealth under the federal COVID-era waiver extended through December 31, 2025. After that, the rules may change — potentially requiring an initial in-person exam for new patients — but existing patients can continue receiving care remotely.

Do I need an in-person visit before prescribing ADHD medication via telehealth?

Currently, no. The DEA waived the Ryan Haight Act’s in-person requirement for controlled substances during COVID, and that waiver has been extended through the end of 2025. If the waiver expires without replacement in 2026, you may need to establish care with an in-person exam for new patients before prescribing stimulants via telehealth.

Can nurse practitioners prescribe ADHD medication?

It depends on the state. In states with Full Practice Authority (like New York after 3,600 hours, or Illinois after 4,000 hours), PMHNPs can prescribe ADHD medications independently. In restricted states like Texas, NPs cannot prescribe Schedule II stimulants in outpatient settings. In states like Florida and Pennsylvania, NPs can prescribe stimulants but only under physician supervision and with quantity or duration limits.

What states allow PMHNPs to prescribe ADHD medication independently?

States where experienced PMHNPs have full independent prescribing authority for ADHD meds include: New York (after 3,600 supervised hours), Illinois (after 4,000 hours + training), and increasingly California (for ‘104 NPs’ with ≥3 years experience). Many other states are transitioning toward NP independence, but as of 2026, most still require collaborative agreements with physicians for Schedule II prescribing.

Does insurance cover telehealth ADHD medication management?

Yes. Nearly all states have telehealth payment parity laws, and Medicare/Medicaid cover telepsychiatry at the same rates as in-person visits. Commercial insurers follow suit. Psychiatrists billing 99213/99214 codes for med checks get the same reimbursement whether the visit is virtual or in-person.

What are the PDMP requirements for prescribing ADHD medication?

Most states require providers to check the state Prescription Drug Monitoring Program (PDMP) before prescribing Schedule II controlled substances. Some states mandate checking before every prescription (like New York), others require it at least once per patient or quarterly. PDMP access is integrated into most telehealth platforms’ e-prescribing workflows.

Can I prescribe ADHD medication across state lines?

Only if you hold an active medical license in the state where the patient is physically located during the visit. You must also comply with that state’s prescribing laws (PDMP checks, e-prescribing mandates, etc.). Many telehealth providers obtain licenses in multiple states through the Interstate Medical Licensure Compact to serve a broader patient base.

How much do psychiatrists get paid for telehealth ADHD visits?

Medicare pays approximately $89-95 for a 99213 (15-minute med check) and $125-136 for a 99214 (25-minute visit). Commercial insurers typically pay $100-180 depending on the code and plan. Medicaid rates are lower (often $40-65). Initial evaluations (90792) reimburse around $188-202 from Medicare. These are the same rates as in-person visits due to telehealth parity laws.

What’s the difference between a psychiatrist and PMHNP for ADHD treatment?

Psychiatrists (MD/DO) have unrestricted prescriptive authority in all states and can independently diagnose and prescribe ADHD medications anywhere. PMHNPs have the same clinical training in psychiatric medication management but face state-specific scope of practice restrictions — some states allow full independence, others require physician collaboration or prohibit Schedule II prescribing entirely. Both are qualified to manage ADHD; the difference is legal, not clinical.

Are there legal risks to prescribing ADHD medication via telehealth?

The main legal risks are: (1) violating federal controlled substance laws if telehealth flexibilities expire and you don’t adapt, (2) failing to comply with state-specific requirements (PDMP checks, e-prescribing, collaborative agreements for NPs), and (3) inadequate documentation or overprescribing (which invites DEA or state board scrutiny). Following standard of care — thorough evaluations, proper documentation, PDMP monitoring — mitigates these risks substantially.

Sources

1. Axios News – ‘COVID-era telehealth prescribing extended again’ (Nov 18, 2024): www.axios.com — DEA and HHS extended telehealth controlled substance flexibilities through December 31, 2025.

2. Florida Statutes §456.47 (Telehealth – Controlled Substances Exceptions): www.flsenate.gov — Florida law explicitly allows telehealth prescribing of Schedule II drugs for psychiatric disorders including ADHD.

3. RxAgent ‘NP Prescriptive Authority by State (2026 Guide)’ (Updated Dec 28, 2025): rxagent.co — Comprehensive state-by-state breakdown of NP scope of practice and controlled substance prescribing authority.

4. Therathink – ‘Insurance Reimbursement Rates for Psychiatrists [2026]’: therathink.com — Detailed Medicare, Medicaid, and commercial insurance reimbursement rates for psychiatric CPT codes.

5. Healing Psychiatry Florida – ‘Psychiatrist Shortage by State – 2026 Report’ (Jan 15, 2026): www.healingpsychiatryflorida.com — State-by-state psychiatrist-to-population ratios and workforce data.

Source:

• https://www.axios.com/2024/09/18/telehealth-services-controlled-substances-congress#:~:text=Why%20it%20matters%3A%20Pandemic,end%20of%20this%20year%20after
• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,the%20third%20temporary%20extension%20of
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=1,disorder
• https://rxagent.co/blog/np-prescribing-authority#:~:text=OK%20%20,day%20%28ongoing%29%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=TN%20%20,NP%3A%20Independent%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=match%20at%20L210%20NY%20,terminal%20illness%2C%20MD%20initiation
• https://rxagent.co/blog/np-prescribing-authority#:~:text=ID%20%20,3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=FL%20%20,NP%3A%20Independent%20%5B3
• https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=also%20limit%20the%20prescribing%20of,shall%20adopt%20by%20rule%20the